STING agonist-3 (trihydrochloride)

STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer[1].

Product Specifications

UNSPSC

12352005

Target

STING

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sting-agonist-3-trihydrochloride.html

Concentration

10mM

Purity

98.36

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C(N)C1=CC=C(N(C(NC(C2=CC(C)=NN2CC)=O)=N3)C/C=C/CN4C5=C(N=C4NC(C6=CC(C)=NN6CC)=O)C=C(C(N)=O)C=C5OCCCO)C3=C1.Cl.Cl.Cl

Molecular Formula

C37H45Cl3N12O6

Molecular Weight

860.19

References & Citations

[1]Adam Kenneth, et al. Heterocyclic amides useful as protein modulators.patent WO2017175147A1|[2]Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity [published correction appears in Nature. 2019 Jun;570 (7761) :E53. doi: 10.1038/s41586-019-1265-5]. Nature. 2018;564 (7736) :439-443.